Latest News

Big multiple sclerosis breakthrough: Phase 1 trial safely resets patients' immune systems and reduces attack on myelin protein

A phase 1 clinical trial for the first treatment to reset the immune system of multiple sclerosis (MS) patients showed the therapy was safe and dramatically reduced patients' immune systems' reactivity to myelin by 50 to 75 percent. The therapy used billions of patients' own specially processed blood cells to create tolerance to myelin, the insulating layer that forms around nerves. In MS, the immune system attacks myelin. The approach left the normal immune system intact.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Recurrent violence linked to substantially higher rates of mental disorders in post-conflict communities

  • Luck affects how we judge reckless actions

  • Motor skill deficiencies linked to autism severity, reseearch says

  • New ultrasound device may add in detecting risk for heart attack, stroke

  • Leaders call for expanded use of medications to combat opioid overdose epidemic

  • Take notes by hand for better long-term comprehension

  • Paying closer attention to attention

  • Small business owners not always worried about being treated fairly, researcher finds

  • Fruitfly study identifies brain circuit that drives daily cycles of rest, activity

  • New genetic brain disorder in humans discovered

  •